<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00658801</url>
  </required_header>
  <id_info>
    <org_study_id>NCCCTS-07-226</org_study_id>
    <nct_id>NCT00658801</nct_id>
  </id_info>
  <brief_title>Study of Respiratory Gated Proton Beam Radiotherapy for Inoperable Pancreas Carcinoma</brief_title>
  <official_title>A Phase II Study of Respiratory Gated Proton Beam Radiotherapy for Inoperable Pancreas Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Center, Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Center, Korea</source>
  <brief_summary>
    <textblock>
      The only curative option for pancreatic cancer patients is surgery, but the patients within&#xD;
      20% of them are possible for a radical surgery. Accordingly, concurrent chemo-radiation&#xD;
      therapy is generally used for palliation of unresectable pancreatic cancer patients. So far,&#xD;
      the use of 5-fluorouracil (5-FU) was the traditional method of chemotherapy. However, these&#xD;
      days, oral anti-cancer medicine, capecitabine(Xeloda®), was developed and considered as an&#xD;
      alternative medicine of 5-fluorouracil (5-FU). Furthermore, according to the recent results&#xD;
      of clinical trials, the clinical use of capecitabine(Xeloda®) with radiation therapy was&#xD;
      proved to be very effective and safe. Proton therapy is a new radiation therapy which&#xD;
      remaining energy is released when they reach the tumor, delivering the most effective dose of&#xD;
      radiation and which can minimize the exposure to normal tissues. The purpose of this trial is&#xD;
      to improve the therapeutic effects by using proton therapy and chemotherapy concurrently.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    difficult to register&#xD;
  </why_stopped>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>all cause mortality</measure>
    <time_frame>two years</time_frame>
  </primary_outcome>
  <enrollment type="Actual">4</enrollment>
  <condition>Pancreatic Cancer</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Respiratory gated proton beam radiotherapy</intervention_name>
    <description>Prescription dose to PTV as according to the following dose escalation schema:&#xD;
Group 1: Tumor size ≤5cm Dose level 1: 60 GyE /20 fx, 3GyE fraction dose, 5 days/week. Dose level 2: 66 GyE /22 fx, 3GyE fraction dose, 5 days/week. Dose level 3: 72 GyE /24 fx, 3GyE fraction dose, 5 days/week.&#xD;
Group 2: 5cm &lt;Tumor size ≤10cm Dose level 1: 54 GyE /18 fx, 3GyE fraction dose, 5 days/week. Dose level 2: 60 GyE /20 fx, 3GyE fraction dose, 5 days/week. Dose level 3: 66 GyE /22 fx, 3GyE fraction dose, 5 days/week.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathologically confirmed adenocarcinoma of the pancreas or a serum CA19-9 level higher&#xD;
             than normal limits and an pancreas cancer-compatible radiological features in one or&#xD;
             more in CT/MRI/PET scans&#xD;
&#xD;
          -  Unresectable disease base on institutional standard criteria of unresectability or&#xD;
             recurrent disease following radical surgery. There is no evidence of metastatic&#xD;
             disease in the major viscera and no peritoneal seeding&#xD;
&#xD;
          -  Patients with biliary or gastroduodenal obstruction must have drainage prior to&#xD;
             starting chemoradiation&#xD;
&#xD;
          -  All malignant disease must be encompassable within a single irradiation field (15x15cm&#xD;
             maximum)&#xD;
&#xD;
          -  All patients must have radiographically assessable disease&#xD;
&#xD;
          -  No previous irradiation to the planned field&#xD;
&#xD;
          -  Age of ≥ 18 years&#xD;
&#xD;
          -  Performance status of 0 to 2 on the Eastern Cooperative Oncology Group (ECOG) score&#xD;
&#xD;
          -  Required Entry Labortory Parameters:&#xD;
&#xD;
               -  WBC count ≥ 2,000/mm3&#xD;
&#xD;
               -  hemoglobin level ≥ 7.5 g/dL&#xD;
&#xD;
               -  platelet count ≥ 100,000/mm3&#xD;
&#xD;
               -  total bilirubin ≤ 2.0 mg/dL (Patients with elevated bilirubin due to obstruction&#xD;
                  should be stented and their bilirubin should be decreased ≤ 2.0 mg/dL prior to&#xD;
                  study entry)&#xD;
&#xD;
               -  creatinine ≤ 3.0 mg/dL&#xD;
&#xD;
          -  Oral intake (including J-tube feeding) of ≥ 1,500 calories/day should be maintained.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  There is evidence of metastasis in the major viscera or peritoneal seeding.&#xD;
&#xD;
          -  Age of &lt; 18 years&#xD;
&#xD;
          -  Previous history of RT adjacent to planned field&#xD;
&#xD;
          -  Poor performance status of 3 to 4 on the Eastern Cooperative Oncology Group (ECOG)&#xD;
             score&#xD;
&#xD;
          -  Pregnant or breast feeding status&#xD;
&#xD;
          -  Previous history uncontrolled other malignancies within 2 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Cancer Center Korea</name>
      <address>
        <city>Goyang</city>
        <state>Gyeonggi</state>
        <zip>410-769</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <study_first_submitted>March 24, 2008</study_first_submitted>
  <study_first_submitted_qc>April 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2008</study_first_posted>
  <last_update_submitted>July 7, 2011</last_update_submitted>
  <last_update_submitted_qc>July 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 8, 2011</last_update_posted>
  <responsible_party>
    <name_title>Tae Hyun Kim</name_title>
    <organization>National Cancer Center Korea</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

